nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfentanil—ALB—Estropipate—osteoporosis	0.139	0.193	CbGbCtD
Alfentanil—CYP3A7—Estradiol—osteoporosis	0.0616	0.0861	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.0616	0.0861	CbGbCtD
Alfentanil—ALB—Estradiol—osteoporosis	0.0575	0.0803	CbGbCtD
Alfentanil—ABCB1—Ethinyl Estradiol—osteoporosis	0.0467	0.0652	CbGbCtD
Alfentanil—CYP3A5—Estradiol—osteoporosis	0.0462	0.0646	CbGbCtD
Alfentanil—CYP3A4—Estropipate—osteoporosis	0.0434	0.0606	CbGbCtD
Alfentanil—CYP3A4—Calcitriol—osteoporosis	0.0434	0.0606	CbGbCtD
Alfentanil—CYP3A4—Ergocalciferol—osteoporosis	0.0347	0.0485	CbGbCtD
Alfentanil—ABCB1—Conjugated Estrogens—osteoporosis	0.0343	0.0479	CbGbCtD
Alfentanil—ABCB1—Estradiol—osteoporosis	0.0301	0.042	CbGbCtD
Alfentanil—CYP3A4—Raloxifene—osteoporosis	0.029	0.0405	CbGbCtD
Alfentanil—CYP3A4—Ethinyl Estradiol—osteoporosis	0.028	0.0391	CbGbCtD
Alfentanil—CYP3A4—Cholecalciferol—osteoporosis	0.0224	0.0312	CbGbCtD
Alfentanil—CYP3A4—Conjugated Estrogens—osteoporosis	0.0205	0.0287	CbGbCtD
Alfentanil—CYP3A4—Estradiol—osteoporosis	0.018	0.0252	CbGbCtD
Alfentanil—Urticaria—Etidronic acid—osteoporosis	0.000667	0.00261	CcSEcCtD
Alfentanil—Bronchospasm—Estradiol—osteoporosis	0.000665	0.0026	CcSEcCtD
Alfentanil—Skin disorder—Calcitriol—osteoporosis	0.000663	0.00259	CcSEcCtD
Alfentanil—Eye disorder—Zoledronate—osteoporosis	0.000656	0.00257	CcSEcCtD
Alfentanil—Cardiac disorder—Zoledronate—osteoporosis	0.000651	0.00255	CcSEcCtD
Alfentanil—Visual impairment—Conjugated Estrogens—osteoporosis	0.000651	0.00255	CcSEcCtD
Alfentanil—Somnolence—Estropipate—osteoporosis	0.000646	0.00253	CcSEcCtD
Alfentanil—Angiopathy—Zoledronate—osteoporosis	0.000637	0.00249	CcSEcCtD
Alfentanil—Immune system disorder—Zoledronate—osteoporosis	0.000634	0.00248	CcSEcCtD
Alfentanil—Mediastinal disorder—Zoledronate—osteoporosis	0.000632	0.00247	CcSEcCtD
Alfentanil—Eye disorder—Conjugated Estrogens—osteoporosis	0.000632	0.00247	CcSEcCtD
Alfentanil—Chills—Zoledronate—osteoporosis	0.00063	0.00246	CcSEcCtD
Alfentanil—Cough—Ethinyl Estradiol—osteoporosis	0.00063	0.00246	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Estropipate—osteoporosis	0.000627	0.00245	CcSEcCtD
Alfentanil—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000627	0.00245	CcSEcCtD
Alfentanil—Arrhythmia—Zoledronate—osteoporosis	0.000627	0.00245	CcSEcCtD
Alfentanil—Fatigue—Estropipate—osteoporosis	0.000626	0.00245	CcSEcCtD
Alfentanil—Pain—Estropipate—osteoporosis	0.000621	0.00243	CcSEcCtD
Alfentanil—Hypersensitivity—Etidronic acid—osteoporosis	0.000619	0.00242	CcSEcCtD
Alfentanil—Loss of consciousness—Risedronate—osteoporosis	0.000618	0.00242	CcSEcCtD
Alfentanil—Mental disorder—Zoledronate—osteoporosis	0.000615	0.00241	CcSEcCtD
Alfentanil—Agitation—Pamidronate—osteoporosis	0.000615	0.00241	CcSEcCtD
Alfentanil—Cough—Risedronate—osteoporosis	0.000614	0.0024	CcSEcCtD
Alfentanil—Angiopathy—Conjugated Estrogens—osteoporosis	0.000613	0.0024	CcSEcCtD
Alfentanil—Pain—Alendronate—osteoporosis	0.000612	0.00239	CcSEcCtD
Alfentanil—Erythema—Zoledronate—osteoporosis	0.000611	0.00239	CcSEcCtD
Alfentanil—Immune system disorder—Conjugated Estrogens—osteoporosis	0.00061	0.00239	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00061	0.00239	CcSEcCtD
Alfentanil—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000609	0.00238	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000608	0.00238	CcSEcCtD
Alfentanil—Hypertension—Risedronate—osteoporosis	0.000607	0.00238	CcSEcCtD
Alfentanil—Somnolence—Calcitriol—osteoporosis	0.000606	0.00237	CcSEcCtD
Alfentanil—Arrhythmia—Conjugated Estrogens—osteoporosis	0.000604	0.00236	CcSEcCtD
Alfentanil—Pain—Raloxifene—osteoporosis	0.000602	0.00236	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000602	0.00235	CcSEcCtD
Alfentanil—Fatigue—Ibandronate—osteoporosis	0.000601	0.00235	CcSEcCtD
Alfentanil—Pain—Ibandronate—osteoporosis	0.000596	0.00233	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000595	0.00233	CcSEcCtD
Alfentanil—Pruritus—Etidronic acid—osteoporosis	0.000594	0.00233	CcSEcCtD
Alfentanil—Mental disorder—Conjugated Estrogens—osteoporosis	0.000592	0.00232	CcSEcCtD
Alfentanil—Feeling abnormal—Alendronate—osteoporosis	0.00059	0.00231	CcSEcCtD
Alfentanil—Erythema—Conjugated Estrogens—osteoporosis	0.000588	0.0023	CcSEcCtD
Alfentanil—Loss of consciousness—Pamidronate—osteoporosis	0.000588	0.0023	CcSEcCtD
Alfentanil—Cough—Pamidronate—osteoporosis	0.000584	0.00228	CcSEcCtD
Alfentanil—Pain—Calcitriol—osteoporosis	0.000583	0.00228	CcSEcCtD
Alfentanil—Convulsion—Pamidronate—osteoporosis	0.000579	0.00227	CcSEcCtD
Alfentanil—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000578	0.00226	CcSEcCtD
Alfentanil—Hypertension—Pamidronate—osteoporosis	0.000577	0.00226	CcSEcCtD
Alfentanil—Urticaria—Estropipate—osteoporosis	0.000577	0.00226	CcSEcCtD
Alfentanil—Vision blurred—Zoledronate—osteoporosis	0.000576	0.00225	CcSEcCtD
Alfentanil—Body temperature increased—Estropipate—osteoporosis	0.000574	0.00225	CcSEcCtD
Alfentanil—Feeling abnormal—Ibandronate—osteoporosis	0.000574	0.00225	CcSEcCtD
Alfentanil—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000572	0.00224	CcSEcCtD
Alfentanil—Urticaria—Alendronate—osteoporosis	0.000569	0.00222	CcSEcCtD
Alfentanil—Epistaxis—Estradiol—osteoporosis	0.000568	0.00222	CcSEcCtD
Alfentanil—Body temperature increased—Alendronate—osteoporosis	0.000566	0.00221	CcSEcCtD
Alfentanil—Nervous system disorder—Risedronate—osteoporosis	0.000563	0.0022	CcSEcCtD
Alfentanil—Agitation—Zoledronate—osteoporosis	0.000561	0.0022	CcSEcCtD
Alfentanil—Skin disorder—Risedronate—osteoporosis	0.000558	0.00218	CcSEcCtD
Alfentanil—Body temperature increased—Raloxifene—osteoporosis	0.000556	0.00218	CcSEcCtD
Alfentanil—Vision blurred—Conjugated Estrogens—osteoporosis	0.000554	0.00217	CcSEcCtD
Alfentanil—Urticaria—Ibandronate—osteoporosis	0.000554	0.00217	CcSEcCtD
Alfentanil—Body temperature increased—Ibandronate—osteoporosis	0.000551	0.00216	CcSEcCtD
Alfentanil—Confusional state—Pamidronate—osteoporosis	0.00055	0.00215	CcSEcCtD
Alfentanil—Anaphylactic shock—Pamidronate—osteoporosis	0.000546	0.00214	CcSEcCtD
Alfentanil—Urticaria—Calcitriol—osteoporosis	0.000542	0.00212	CcSEcCtD
Alfentanil—Body temperature increased—Calcitriol—osteoporosis	0.000539	0.00211	CcSEcCtD
Alfentanil—Loss of consciousness—Zoledronate—osteoporosis	0.000537	0.0021	CcSEcCtD
Alfentanil—Hypersensitivity—Estropipate—osteoporosis	0.000535	0.00209	CcSEcCtD
Alfentanil—Nervous system disorder—Pamidronate—osteoporosis	0.000535	0.00209	CcSEcCtD
Alfentanil—Vomiting—Etidronic acid—osteoporosis	0.000534	0.00209	CcSEcCtD
Alfentanil—Cough—Zoledronate—osteoporosis	0.000533	0.00209	CcSEcCtD
Alfentanil—Tachycardia—Pamidronate—osteoporosis	0.000533	0.00208	CcSEcCtD
Alfentanil—Connective tissue disorder—Estradiol—osteoporosis	0.000531	0.00208	CcSEcCtD
Alfentanil—Rash—Etidronic acid—osteoporosis	0.00053	0.00207	CcSEcCtD
Alfentanil—Convulsion—Zoledronate—osteoporosis	0.000529	0.00207	CcSEcCtD
Alfentanil—Dermatitis—Etidronic acid—osteoporosis	0.000529	0.00207	CcSEcCtD
Alfentanil—Hyperhidrosis—Pamidronate—osteoporosis	0.000528	0.00206	CcSEcCtD
Alfentanil—Hypertension—Zoledronate—osteoporosis	0.000527	0.00206	CcSEcCtD
Alfentanil—Hypersensitivity—Alendronate—osteoporosis	0.000527	0.00206	CcSEcCtD
Alfentanil—Headache—Etidronic acid—osteoporosis	0.000526	0.00206	CcSEcCtD
Alfentanil—Asthenia—Estropipate—osteoporosis	0.000521	0.00204	CcSEcCtD
Alfentanil—Visual impairment—Estradiol—osteoporosis	0.000521	0.00204	CcSEcCtD
Alfentanil—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000517	0.00202	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000517	0.00202	CcSEcCtD
Alfentanil—Pruritus—Estropipate—osteoporosis	0.000514	0.00201	CcSEcCtD
Alfentanil—Asthenia—Alendronate—osteoporosis	0.000513	0.00201	CcSEcCtD
Alfentanil—Hypersensitivity—Ibandronate—osteoporosis	0.000513	0.00201	CcSEcCtD
Alfentanil—Cough—Conjugated Estrogens—osteoporosis	0.000513	0.00201	CcSEcCtD
Alfentanil—Hypotension—Pamidronate—osteoporosis	0.00051	0.002	CcSEcCtD
Alfentanil—Convulsion—Conjugated Estrogens—osteoporosis	0.00051	0.00199	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000508	0.00199	CcSEcCtD
Alfentanil—Fatigue—Ethinyl Estradiol—osteoporosis	0.000508	0.00199	CcSEcCtD
Alfentanil—Pruritus—Alendronate—osteoporosis	0.000506	0.00198	CcSEcCtD
Alfentanil—Eye disorder—Estradiol—osteoporosis	0.000505	0.00198	CcSEcCtD
Alfentanil—Confusional state—Zoledronate—osteoporosis	0.000503	0.00197	CcSEcCtD
Alfentanil—Hypersensitivity—Calcitriol—osteoporosis	0.000503	0.00197	CcSEcCtD
Alfentanil—Cardiac disorder—Estradiol—osteoporosis	0.000502	0.00196	CcSEcCtD
Alfentanil—Asthenia—Ibandronate—osteoporosis	0.0005	0.00196	CcSEcCtD
Alfentanil—Nausea—Etidronic acid—osteoporosis	0.000499	0.00195	CcSEcCtD
Alfentanil—Anaphylactic shock—Zoledronate—osteoporosis	0.000499	0.00195	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000497	0.00195	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Risedronate—osteoporosis	0.000496	0.00194	CcSEcCtD
Alfentanil—Fatigue—Risedronate—osteoporosis	0.000495	0.00194	CcSEcCtD
Alfentanil—Pruritus—Ibandronate—osteoporosis	0.000493	0.00193	CcSEcCtD
Alfentanil—Pain—Risedronate—osteoporosis	0.000491	0.00192	CcSEcCtD
Alfentanil—Angiopathy—Estradiol—osteoporosis	0.000491	0.00192	CcSEcCtD
Alfentanil—Asthenia—Calcitriol—osteoporosis	0.000489	0.00191	CcSEcCtD
Alfentanil—Nervous system disorder—Zoledronate—osteoporosis	0.000489	0.00191	CcSEcCtD
Alfentanil—Immune system disorder—Estradiol—osteoporosis	0.000489	0.00191	CcSEcCtD
Alfentanil—Mediastinal disorder—Estradiol—osteoporosis	0.000487	0.00191	CcSEcCtD
Alfentanil—Tachycardia—Zoledronate—osteoporosis	0.000487	0.0019	CcSEcCtD
Alfentanil—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000485	0.0019	CcSEcCtD
Alfentanil—Chills—Estradiol—osteoporosis	0.000485	0.0019	CcSEcCtD
Alfentanil—Somnolence—Pamidronate—osteoporosis	0.000485	0.0019	CcSEcCtD
Alfentanil—Skin disorder—Zoledronate—osteoporosis	0.000484	0.0019	CcSEcCtD
Alfentanil—Pruritus—Calcitriol—osteoporosis	0.000483	0.00189	CcSEcCtD
Alfentanil—Hyperhidrosis—Zoledronate—osteoporosis	0.000482	0.00189	CcSEcCtD
Alfentanil—Dizziness—Estropipate—osteoporosis	0.00048	0.00188	CcSEcCtD
Alfentanil—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00048	0.00188	CcSEcCtD
Alfentanil—Mental disorder—Estradiol—osteoporosis	0.000474	0.00185	CcSEcCtD
Alfentanil—Dizziness—Alendronate—osteoporosis	0.000473	0.00185	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000471	0.00184	CcSEcCtD
Alfentanil—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000471	0.00184	CcSEcCtD
Alfentanil—Erythema—Estradiol—osteoporosis	0.000471	0.00184	CcSEcCtD
Alfentanil—Fatigue—Pamidronate—osteoporosis	0.000471	0.00184	CcSEcCtD
Alfentanil—Tachycardia—Conjugated Estrogens—osteoporosis	0.000469	0.00183	CcSEcCtD
Alfentanil—Urticaria—Ethinyl Estradiol—osteoporosis	0.000468	0.00183	CcSEcCtD
Alfentanil—Pain—Pamidronate—osteoporosis	0.000467	0.00183	CcSEcCtD
Alfentanil—Skin disorder—Conjugated Estrogens—osteoporosis	0.000466	0.00182	CcSEcCtD
Alfentanil—Hypotension—Zoledronate—osteoporosis	0.000466	0.00182	CcSEcCtD
Alfentanil—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000466	0.00182	CcSEcCtD
Alfentanil—Dizziness—Raloxifene—osteoporosis	0.000465	0.00182	CcSEcCtD
Alfentanil—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000464	0.00182	CcSEcCtD
Alfentanil—Vomiting—Estropipate—osteoporosis	0.000462	0.00181	CcSEcCtD
Alfentanil—Dizziness—Ibandronate—osteoporosis	0.000461	0.0018	CcSEcCtD
Alfentanil—Rash—Estropipate—osteoporosis	0.000458	0.00179	CcSEcCtD
Alfentanil—Dermatitis—Estropipate—osteoporosis	0.000458	0.00179	CcSEcCtD
Alfentanil—Urticaria—Risedronate—osteoporosis	0.000456	0.00178	CcSEcCtD
Alfentanil—Headache—Estropipate—osteoporosis	0.000455	0.00178	CcSEcCtD
Alfentanil—Vomiting—Alendronate—osteoporosis	0.000455	0.00178	CcSEcCtD
Alfentanil—Body temperature increased—Risedronate—osteoporosis	0.000454	0.00178	CcSEcCtD
Alfentanil—Rash—Alendronate—osteoporosis	0.000451	0.00177	CcSEcCtD
Alfentanil—Dermatitis—Alendronate—osteoporosis	0.000451	0.00176	CcSEcCtD
Alfentanil—Feeling abnormal—Pamidronate—osteoporosis	0.00045	0.00176	CcSEcCtD
Alfentanil—Hypotension—Conjugated Estrogens—osteoporosis	0.000449	0.00176	CcSEcCtD
Alfentanil—Headache—Alendronate—osteoporosis	0.000448	0.00175	CcSEcCtD
Alfentanil—Vomiting—Raloxifene—osteoporosis	0.000447	0.00175	CcSEcCtD
Alfentanil—Rash—Raloxifene—osteoporosis	0.000444	0.00174	CcSEcCtD
Alfentanil—Dermatitis—Raloxifene—osteoporosis	0.000443	0.00173	CcSEcCtD
Alfentanil—Somnolence—Zoledronate—osteoporosis	0.000443	0.00173	CcSEcCtD
Alfentanil—Vomiting—Ibandronate—osteoporosis	0.000443	0.00173	CcSEcCtD
Alfentanil—Headache—Raloxifene—osteoporosis	0.000441	0.00173	CcSEcCtD
Alfentanil—Rash—Ibandronate—osteoporosis	0.000439	0.00172	CcSEcCtD
Alfentanil—Dermatitis—Ibandronate—osteoporosis	0.000439	0.00172	CcSEcCtD
Alfentanil—Headache—Ibandronate—osteoporosis	0.000436	0.00171	CcSEcCtD
Alfentanil—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000434	0.0017	CcSEcCtD
Alfentanil—Vomiting—Calcitriol—osteoporosis	0.000434	0.0017	CcSEcCtD
Alfentanil—Agitation—Estradiol—osteoporosis	0.000433	0.00169	CcSEcCtD
Alfentanil—Nausea—Estropipate—osteoporosis	0.000432	0.00169	CcSEcCtD
Alfentanil—Body temperature increased—Pamidronate—osteoporosis	0.000432	0.00169	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00043	0.00168	CcSEcCtD
Alfentanil—Rash—Calcitriol—osteoporosis	0.00043	0.00168	CcSEcCtD
Alfentanil—Fatigue—Zoledronate—osteoporosis	0.00043	0.00168	CcSEcCtD
Alfentanil—Dermatitis—Calcitriol—osteoporosis	0.00043	0.00168	CcSEcCtD
Alfentanil—Headache—Calcitriol—osteoporosis	0.000427	0.00167	CcSEcCtD
Alfentanil—Somnolence—Conjugated Estrogens—osteoporosis	0.000427	0.00167	CcSEcCtD
Alfentanil—Pain—Zoledronate—osteoporosis	0.000426	0.00167	CcSEcCtD
Alfentanil—Nausea—Alendronate—osteoporosis	0.000425	0.00166	CcSEcCtD
Alfentanil—Hypersensitivity—Risedronate—osteoporosis	0.000423	0.00166	CcSEcCtD
Alfentanil—Asthenia—Ethinyl Estradiol—osteoporosis	0.000423	0.00165	CcSEcCtD
Alfentanil—Nausea—Raloxifene—osteoporosis	0.000418	0.00164	CcSEcCtD
Alfentanil—Pruritus—Ethinyl Estradiol—osteoporosis	0.000417	0.00163	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000414	0.00162	CcSEcCtD
Alfentanil—Fatigue—Conjugated Estrogens—osteoporosis	0.000414	0.00162	CcSEcCtD
Alfentanil—Nausea—Ibandronate—osteoporosis	0.000414	0.00162	CcSEcCtD
Alfentanil—Loss of consciousness—Estradiol—osteoporosis	0.000414	0.00162	CcSEcCtD
Alfentanil—Asthenia—Risedronate—osteoporosis	0.000412	0.00161	CcSEcCtD
Alfentanil—Feeling abnormal—Zoledronate—osteoporosis	0.000411	0.00161	CcSEcCtD
Alfentanil—Cough—Estradiol—osteoporosis	0.000411	0.00161	CcSEcCtD
Alfentanil—Pain—Conjugated Estrogens—osteoporosis	0.000411	0.00161	CcSEcCtD
Alfentanil—Hypertension—Estradiol—osteoporosis	0.000406	0.00159	CcSEcCtD
Alfentanil—Pruritus—Risedronate—osteoporosis	0.000406	0.00159	CcSEcCtD
Alfentanil—Nausea—Calcitriol—osteoporosis	0.000405	0.00159	CcSEcCtD
Alfentanil—Hypersensitivity—Pamidronate—osteoporosis	0.000402	0.00157	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000398	0.00156	CcSEcCtD
Alfentanil—Urticaria—Zoledronate—osteoporosis	0.000396	0.00155	CcSEcCtD
Alfentanil—Body temperature increased—Zoledronate—osteoporosis	0.000394	0.00154	CcSEcCtD
Alfentanil—Asthenia—Pamidronate—osteoporosis	0.000392	0.00153	CcSEcCtD
Alfentanil—Dizziness—Ethinyl Estradiol—osteoporosis	0.000389	0.00152	CcSEcCtD
Alfentanil—Confusional state—Estradiol—osteoporosis	0.000387	0.00152	CcSEcCtD
Alfentanil—Pruritus—Pamidronate—osteoporosis	0.000386	0.00151	CcSEcCtD
Alfentanil—Anaphylactic shock—Estradiol—osteoporosis	0.000384	0.0015	CcSEcCtD
Alfentanil—Urticaria—Conjugated Estrogens—osteoporosis	0.000381	0.00149	CcSEcCtD
Alfentanil—Dizziness—Risedronate—osteoporosis	0.00038	0.00149	CcSEcCtD
Alfentanil—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00038	0.00149	CcSEcCtD
Alfentanil—Nervous system disorder—Estradiol—osteoporosis	0.000377	0.00147	CcSEcCtD
Alfentanil—Tachycardia—Estradiol—osteoporosis	0.000375	0.00147	CcSEcCtD
Alfentanil—Vomiting—Ethinyl Estradiol—osteoporosis	0.000374	0.00147	CcSEcCtD
Alfentanil—Skin disorder—Estradiol—osteoporosis	0.000373	0.00146	CcSEcCtD
Alfentanil—Hyperhidrosis—Estradiol—osteoporosis	0.000371	0.00145	CcSEcCtD
Alfentanil—Rash—Ethinyl Estradiol—osteoporosis	0.000371	0.00145	CcSEcCtD
Alfentanil—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000371	0.00145	CcSEcCtD
Alfentanil—Headache—Ethinyl Estradiol—osteoporosis	0.000369	0.00144	CcSEcCtD
Alfentanil—Hypersensitivity—Zoledronate—osteoporosis	0.000367	0.00144	CcSEcCtD
Alfentanil—Vomiting—Risedronate—osteoporosis	0.000365	0.00143	CcSEcCtD
Alfentanil—Rash—Risedronate—osteoporosis	0.000362	0.00142	CcSEcCtD
Alfentanil—Dermatitis—Risedronate—osteoporosis	0.000362	0.00142	CcSEcCtD
Alfentanil—Dizziness—Pamidronate—osteoporosis	0.000361	0.00141	CcSEcCtD
Alfentanil—Headache—Risedronate—osteoporosis	0.00036	0.00141	CcSEcCtD
Alfentanil—Asthenia—Zoledronate—osteoporosis	0.000358	0.0014	CcSEcCtD
Alfentanil—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000354	0.00138	CcSEcCtD
Alfentanil—Pruritus—Zoledronate—osteoporosis	0.000353	0.00138	CcSEcCtD
Alfentanil—Nausea—Ethinyl Estradiol—osteoporosis	0.00035	0.00137	CcSEcCtD
Alfentanil—Vomiting—Pamidronate—osteoporosis	0.000347	0.00136	CcSEcCtD
Alfentanil—Asthenia—Conjugated Estrogens—osteoporosis	0.000344	0.00135	CcSEcCtD
Alfentanil—Rash—Pamidronate—osteoporosis	0.000344	0.00135	CcSEcCtD
Alfentanil—Dermatitis—Pamidronate—osteoporosis	0.000344	0.00135	CcSEcCtD
Alfentanil—Headache—Pamidronate—osteoporosis	0.000342	0.00134	CcSEcCtD
Alfentanil—Somnolence—Estradiol—osteoporosis	0.000342	0.00134	CcSEcCtD
Alfentanil—Nausea—Risedronate—osteoporosis	0.000341	0.00133	CcSEcCtD
Alfentanil—Pruritus—Conjugated Estrogens—osteoporosis	0.00034	0.00133	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Estradiol—osteoporosis	0.000332	0.0013	CcSEcCtD
Alfentanil—Fatigue—Estradiol—osteoporosis	0.000331	0.0013	CcSEcCtD
Alfentanil—Dizziness—Zoledronate—osteoporosis	0.00033	0.00129	CcSEcCtD
Alfentanil—Pain—Estradiol—osteoporosis	0.000329	0.00129	CcSEcCtD
Alfentanil—Nausea—Pamidronate—osteoporosis	0.000324	0.00127	CcSEcCtD
Alfentanil—Dizziness—Conjugated Estrogens—osteoporosis	0.000317	0.00124	CcSEcCtD
Alfentanil—Vomiting—Zoledronate—osteoporosis	0.000317	0.00124	CcSEcCtD
Alfentanil—Feeling abnormal—Estradiol—osteoporosis	0.000317	0.00124	CcSEcCtD
Alfentanil—Rash—Zoledronate—osteoporosis	0.000314	0.00123	CcSEcCtD
Alfentanil—Dermatitis—Zoledronate—osteoporosis	0.000314	0.00123	CcSEcCtD
Alfentanil—Headache—Zoledronate—osteoporosis	0.000312	0.00122	CcSEcCtD
Alfentanil—Vomiting—Conjugated Estrogens—osteoporosis	0.000305	0.00119	CcSEcCtD
Alfentanil—Urticaria—Estradiol—osteoporosis	0.000305	0.00119	CcSEcCtD
Alfentanil—Body temperature increased—Estradiol—osteoporosis	0.000304	0.00119	CcSEcCtD
Alfentanil—Rash—Conjugated Estrogens—osteoporosis	0.000303	0.00118	CcSEcCtD
Alfentanil—Dermatitis—Conjugated Estrogens—osteoporosis	0.000302	0.00118	CcSEcCtD
Alfentanil—Headache—Conjugated Estrogens—osteoporosis	0.000301	0.00118	CcSEcCtD
Alfentanil—Nausea—Zoledronate—osteoporosis	0.000296	0.00116	CcSEcCtD
Alfentanil—Nausea—Conjugated Estrogens—osteoporosis	0.000285	0.00112	CcSEcCtD
Alfentanil—Hypersensitivity—Estradiol—osteoporosis	0.000283	0.00111	CcSEcCtD
Alfentanil—Asthenia—Estradiol—osteoporosis	0.000276	0.00108	CcSEcCtD
Alfentanil—Pruritus—Estradiol—osteoporosis	0.000272	0.00106	CcSEcCtD
Alfentanil—Dizziness—Estradiol—osteoporosis	0.000254	0.000994	CcSEcCtD
Alfentanil—Vomiting—Estradiol—osteoporosis	0.000244	0.000956	CcSEcCtD
Alfentanil—Rash—Estradiol—osteoporosis	0.000242	0.000948	CcSEcCtD
Alfentanil—Dermatitis—Estradiol—osteoporosis	0.000242	0.000947	CcSEcCtD
Alfentanil—Headache—Estradiol—osteoporosis	0.000241	0.000942	CcSEcCtD
Alfentanil—Nausea—Estradiol—osteoporosis	0.000228	0.000893	CcSEcCtD
Alfentanil—CYP3A5—Phase 1 - Functionalization of compounds—POMC—osteoporosis	8.14e-05	0.00288	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—MTHFR—osteoporosis	7.96e-05	0.00282	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	7.89e-05	0.00279	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—WNT1—osteoporosis	7.88e-05	0.00279	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—RAP1A—osteoporosis	7.85e-05	0.00278	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—CAP1—osteoporosis	7.84e-05	0.00277	CbGpPWpGaD
Alfentanil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	7.77e-05	0.00275	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	7.73e-05	0.00274	CbGpPWpGaD
Alfentanil—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	7.67e-05	0.00271	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	7.48e-05	0.00265	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—ADCY5—osteoporosis	7.37e-05	0.00261	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—MGLL—osteoporosis	7.35e-05	0.0026	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—IL1B—osteoporosis	7.31e-05	0.00259	CbGpPWpGaD
Alfentanil—CYP3A5—Biological oxidations—CYP19A1—osteoporosis	7.2e-05	0.00255	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—PTHLH—osteoporosis	7.13e-05	0.00252	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—FGA—osteoporosis	7.12e-05	0.00252	CbGpPWpGaD
Alfentanil—CYP3A5—Metapathway biotransformation—CYP19A1—osteoporosis	7.1e-05	0.00251	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—TGFB1—osteoporosis	6.74e-05	0.00238	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—MGLL—osteoporosis	6.67e-05	0.00236	CbGpPWpGaD
Alfentanil—ALB—Platelet degranulation—IGF1—osteoporosis	6.61e-05	0.00234	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—FGB—osteoporosis	6.48e-05	0.00229	CbGpPWpGaD
Alfentanil—OPRM1—Peptide ligand-binding receptors—POMC—osteoporosis	6.43e-05	0.00227	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	6.37e-05	0.00225	CbGpPWpGaD
Alfentanil—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	6.3e-05	0.00223	CbGpPWpGaD
Alfentanil—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—osteoporosis	6.3e-05	0.00223	CbGpPWpGaD
Alfentanil—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	6.28e-05	0.00222	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CALCA—osteoporosis	6.27e-05	0.00222	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—MGLL—osteoporosis	6.23e-05	0.0022	CbGpPWpGaD
Alfentanil—CYP3A7—Biological oxidations—POMC—osteoporosis	5.98e-05	0.00212	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IL1B—osteoporosis	5.95e-05	0.00211	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.82e-05	0.00206	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—PLEK—osteoporosis	5.7e-05	0.00202	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—ANXA2—osteoporosis	5.7e-05	0.00202	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.67e-05	0.00201	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—FDPS—osteoporosis	5.64e-05	0.002	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PKM—osteoporosis	5.64e-05	0.002	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	5.5e-05	0.00195	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—SOST—osteoporosis	5.49e-05	0.00194	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—POMC—osteoporosis	5.42e-05	0.00192	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PGLS—osteoporosis	5.35e-05	0.00189	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GPD2—osteoporosis	5.35e-05	0.00189	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—TNF—osteoporosis	5.31e-05	0.00188	CbGpPWpGaD
Alfentanil—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	5.15e-05	0.00182	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—IL6—osteoporosis	5.08e-05	0.0018	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CALCR—osteoporosis	4.96e-05	0.00176	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PTH1R—osteoporosis	4.96e-05	0.00176	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—ANXA2—osteoporosis	4.93e-05	0.00174	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—TLN1—osteoporosis	4.91e-05	0.00174	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PNP—osteoporosis	4.89e-05	0.00173	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ATIC—osteoporosis	4.89e-05	0.00173	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—PTH—osteoporosis	4.86e-05	0.00172	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—VCL—osteoporosis	4.84e-05	0.00171	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CNR2—osteoporosis	4.74e-05	0.00168	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—IL1B—osteoporosis	4.73e-05	0.00167	CbGpPWpGaD
Alfentanil—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.67e-05	0.00165	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.53e-05	0.0016	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IL1B—osteoporosis	4.51e-05	0.0016	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—PTH—osteoporosis	4.41e-05	0.00156	CbGpPWpGaD
Alfentanil—CYP3A5—Biological oxidations—POMC—osteoporosis	4.33e-05	0.00153	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	4.32e-05	0.00153	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—TNF—osteoporosis	4.32e-05	0.00153	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	4.31e-05	0.00153	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CNR2—osteoporosis	4.3e-05	0.00152	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—IL6—osteoporosis	4.28e-05	0.00152	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CA2—osteoporosis	4.16e-05	0.00147	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—OXCT1—osteoporosis	4.16e-05	0.00147	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—FDPS—osteoporosis	4.08e-05	0.00144	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PKM—osteoporosis	4.08e-05	0.00144	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—MGLL—osteoporosis	4.06e-05	0.00144	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—RAP1A—osteoporosis	4.05e-05	0.00143	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—WNT1—osteoporosis	4.04e-05	0.00143	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—PTHLH—osteoporosis	4.03e-05	0.00143	CbGpPWpGaD
Alfentanil—ALB—Platelet degranulation—TGFB1—osteoporosis	3.96e-05	0.0014	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MGLL—osteoporosis	3.94e-05	0.0014	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GPD2—osteoporosis	3.87e-05	0.00137	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PGLS—osteoporosis	3.87e-05	0.00137	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.85e-05	0.00136	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—LRP5—osteoporosis	3.85e-05	0.00136	CbGpPWpGaD
Alfentanil—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.79e-05	0.00134	CbGpPWpGaD
Alfentanil—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoporosis	3.78e-05	0.00134	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—LRP6—osteoporosis	3.68e-05	0.0013	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—FGA—osteoporosis	3.67e-05	0.0013	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—PTHLH—osteoporosis	3.66e-05	0.00129	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CALCA—osteoporosis	3.55e-05	0.00125	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ATIC—osteoporosis	3.54e-05	0.00125	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PNP—osteoporosis	3.54e-05	0.00125	CbGpPWpGaD
Alfentanil—ALB—Metabolism—FDPS—osteoporosis	3.51e-05	0.00124	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PKM—osteoporosis	3.51e-05	0.00124	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—TGFB1—osteoporosis	3.51e-05	0.00124	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IL6—osteoporosis	3.48e-05	0.00123	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—IDH2—osteoporosis	3.45e-05	0.00122	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—TNF—osteoporosis	3.43e-05	0.00121	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3.35e-05	0.00118	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—FGB—osteoporosis	3.34e-05	0.00118	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.34e-05	0.00118	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GPD2—osteoporosis	3.33e-05	0.00118	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PGLS—osteoporosis	3.33e-05	0.00118	CbGpPWpGaD
Alfentanil—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	3.3e-05	0.00117	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—POMC—osteoporosis	3.28e-05	0.00116	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—TNF—osteoporosis	3.28e-05	0.00116	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CYP27A1—osteoporosis	3.24e-05	0.00115	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CALCA—osteoporosis	3.22e-05	0.00114	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ACP5—osteoporosis	3.15e-05	0.00112	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TLN1—osteoporosis	3.11e-05	0.0011	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—FDPS—osteoporosis	3.08e-05	0.00109	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PKM—osteoporosis	3.08e-05	0.00109	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ATIC—osteoporosis	3.05e-05	0.00108	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PNP—osteoporosis	3.05e-05	0.00108	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—OXCT1—osteoporosis	3.01e-05	0.00106	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CA2—osteoporosis	3.01e-05	0.00106	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—IGF1—osteoporosis	2.93e-05	0.00104	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—TPI1—osteoporosis	2.93e-05	0.00104	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—MGLL—osteoporosis	2.93e-05	0.00104	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PGLS—osteoporosis	2.92e-05	0.00103	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GPD2—osteoporosis	2.92e-05	0.00103	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.89e-05	0.00102	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—IL6—osteoporosis	2.77e-05	0.000979	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—P4HB—osteoporosis	2.76e-05	0.000975	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GAPDH—osteoporosis	2.71e-05	0.000957	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—P4HB—osteoporosis	2.68e-05	0.000948	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ATIC—osteoporosis	2.67e-05	0.000945	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PNP—osteoporosis	2.67e-05	0.000945	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—RAP1A—osteoporosis	2.64e-05	0.000933	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PTH—osteoporosis	2.61e-05	0.000923	CbGpPWpGaD
Alfentanil—ALB—Metabolism—OXCT1—osteoporosis	2.59e-05	0.000917	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CA2—osteoporosis	2.59e-05	0.000917	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—RAP1A—osteoporosis	2.56e-05	0.000907	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CNR2—osteoporosis	2.54e-05	0.000899	CbGpPWpGaD
Alfentanil—ALB—Metabolism—MGLL—osteoporosis	2.52e-05	0.000893	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—ADCY5—osteoporosis	2.52e-05	0.000892	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—NFATC1—osteoporosis	2.5e-05	0.000885	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—IDH2—osteoporosis	2.49e-05	0.000882	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—DKK1—osteoporosis	2.48e-05	0.000878	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—WNT1—osteoporosis	2.39e-05	0.000845	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.38e-05	0.000842	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CYP27A1—osteoporosis	2.34e-05	0.000829	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—FGA—osteoporosis	2.32e-05	0.000822	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—ADCY5—osteoporosis	2.29e-05	0.00081	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ACP5—osteoporosis	2.28e-05	0.000807	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CA2—osteoporosis	2.27e-05	0.000803	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—OXCT1—osteoporosis	2.27e-05	0.000803	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—MGLL—osteoporosis	2.21e-05	0.000783	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PTHLH—osteoporosis	2.16e-05	0.000764	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—BMP2—osteoporosis	2.16e-05	0.000764	CbGpPWpGaD
Alfentanil—ALB—Metabolism—IDH2—osteoporosis	2.15e-05	0.00076	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ENO1—osteoporosis	2.13e-05	0.000754	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—TPI1—osteoporosis	2.12e-05	0.00075	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—FGB—osteoporosis	2.11e-05	0.000748	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PSMA5—osteoporosis	2.1e-05	0.000743	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PSMA2—osteoporosis	2.1e-05	0.000743	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PSMA2—osteoporosis	2.04e-05	0.000722	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PSMA5—osteoporosis	2.04e-05	0.000722	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP27A1—osteoporosis	2.02e-05	0.000714	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—POMC—osteoporosis	2.01e-05	0.000712	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—P4HB—osteoporosis	1.99e-05	0.000705	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ACP5—osteoporosis	1.96e-05	0.000695	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GAPDH—osteoporosis	1.96e-05	0.000692	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.94e-05	0.000686	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—RAP1A—osteoporosis	1.9e-05	0.000674	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CALCA—osteoporosis	1.9e-05	0.000673	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PKM—osteoporosis	1.9e-05	0.000671	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—FDPS—osteoporosis	1.9e-05	0.000671	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—IDH2—osteoporosis	1.88e-05	0.000666	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—POMC—osteoporosis	1.85e-05	0.000656	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.85e-05	0.000654	CbGpPWpGaD
Alfentanil—ALB—Metabolism—TPI1—osteoporosis	1.83e-05	0.000646	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PGLS—osteoporosis	1.8e-05	0.000636	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GPD2—osteoporosis	1.8e-05	0.000636	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP27A1—osteoporosis	1.77e-05	0.000626	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	1.76e-05	0.000622	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.74e-05	0.000614	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.73e-05	0.000613	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—KL—osteoporosis	1.73e-05	0.000611	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ACP5—osteoporosis	1.72e-05	0.000609	CbGpPWpGaD
Alfentanil—ALB—Metabolism—P4HB—osteoporosis	1.72e-05	0.000607	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CYP19A1—osteoporosis	1.7e-05	0.000603	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—POMC—osteoporosis	1.68e-05	0.000596	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GAPDH—osteoporosis	1.68e-05	0.000596	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PNP—osteoporosis	1.64e-05	0.000582	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ATIC—osteoporosis	1.64e-05	0.000582	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—IL6R—osteoporosis	1.64e-05	0.000581	CbGpPWpGaD
Alfentanil—ALB—Metabolism—RAP1A—osteoporosis	1.64e-05	0.000581	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.62e-05	0.000573	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.62e-05	0.000572	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—TPI1—osteoporosis	1.6e-05	0.000566	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ENO1—osteoporosis	1.54e-05	0.000545	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PSMA2—osteoporosis	1.52e-05	0.000537	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PSMA5—osteoporosis	1.52e-05	0.000537	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IGF1—osteoporosis	1.51e-05	0.000535	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—P4HB—osteoporosis	1.5e-05	0.000532	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GAPDH—osteoporosis	1.48e-05	0.000522	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—RAP1A—osteoporosis	1.44e-05	0.000509	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.43e-05	0.000506	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—OXCT1—osteoporosis	1.4e-05	0.000495	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CA2—osteoporosis	1.4e-05	0.000495	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ADCY5—osteoporosis	1.39e-05	0.000492	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GPX1—osteoporosis	1.39e-05	0.000491	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—MGLL—osteoporosis	1.36e-05	0.000482	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—ADCY5—osteoporosis	1.35e-05	0.000479	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ENO1—osteoporosis	1.33e-05	0.000469	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—SPP1—osteoporosis	1.31e-05	0.000463	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PSMA2—osteoporosis	1.31e-05	0.000462	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PSMA5—osteoporosis	1.31e-05	0.000462	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—MTHFR—osteoporosis	1.28e-05	0.000453	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CYP19A1—osteoporosis	1.23e-05	0.000436	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IRS2—osteoporosis	1.18e-05	0.000419	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ENO1—osteoporosis	1.16e-05	0.000411	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—IDH2—osteoporosis	1.16e-05	0.00041	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—LEP—osteoporosis	1.16e-05	0.00041	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PSMA2—osteoporosis	1.15e-05	0.000405	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PSMA5—osteoporosis	1.15e-05	0.000405	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—ESR1—osteoporosis	1.11e-05	0.000391	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.09e-05	0.000386	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP19A1—osteoporosis	1.06e-05	0.000375	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ACP5—osteoporosis	1.06e-05	0.000375	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IRS1—osteoporosis	1.03e-05	0.000366	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—POMC—osteoporosis	1.02e-05	0.000362	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ADCY5—osteoporosis	1.01e-05	0.000356	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GPX1—osteoporosis	1e-05	0.000355	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—POMC—osteoporosis	9.95e-06	0.000352	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—TPI1—osteoporosis	9.85e-06	0.000349	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL6R—osteoporosis	9.71e-06	0.000343	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IGF1—osteoporosis	9.57e-06	0.000339	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP19A1—osteoporosis	9.29e-06	0.000329	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—P4HB—osteoporosis	9.26e-06	0.000328	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—MTHFR—osteoporosis	9.25e-06	0.000327	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GAPDH—osteoporosis	9.09e-06	0.000322	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—TGFB1—osteoporosis	9.06e-06	0.000321	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—RAP1A—osteoporosis	8.86e-06	0.000313	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ADCY5—osteoporosis	8.66e-06	0.000307	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GPX1—osteoporosis	8.63e-06	0.000305	CbGpPWpGaD
Alfentanil—ALB—Metabolism—MTHFR—osteoporosis	7.97e-06	0.000282	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ADCY5—osteoporosis	7.59e-06	0.000269	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GPX1—osteoporosis	7.56e-06	0.000268	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—POMC—osteoporosis	7.4e-06	0.000262	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—IL6—osteoporosis	7.32e-06	0.000259	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ENO1—osteoporosis	7.16e-06	0.000253	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PSMA2—osteoporosis	7.05e-06	0.00025	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PSMA5—osteoporosis	7.05e-06	0.00025	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—MTHFR—osteoporosis	6.98e-06	0.000247	CbGpPWpGaD
Alfentanil—ALB—Metabolism—POMC—osteoporosis	6.37e-06	0.000225	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MYC—osteoporosis	5.75e-06	0.000204	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TGFB1—osteoporosis	5.74e-06	0.000203	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP19A1—osteoporosis	5.72e-06	0.000203	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—POMC—osteoporosis	5.58e-06	0.000198	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ADCY5—osteoporosis	4.68e-06	0.000165	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GPX1—osteoporosis	4.66e-06	0.000165	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL6—osteoporosis	4.32e-06	0.000153	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—MTHFR—osteoporosis	4.3e-06	0.000152	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—POMC—osteoporosis	3.44e-06	0.000122	CbGpPWpGaD
